Literature DB >> 27572406

Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Muhammad-Hariri Mustafa1,2, Hussein Chalhoub1, Olivier Denis3, Ariane Deplano3, Anne Vergison3, Hector Rodriguez-Villalobos4, Michael M Tunney5, J Stuart Elborn5, Barbara C Kahl6, Hamidou Traore2, Francis Vanderbist2, Paul M Tulkens1, Françoise Van Bambeke7.   

Abstract

Pseudomonas aeruginosa is a major cause of morbidity and mortality in cystic fibrosis patients. This study compared the antimicrobial susceptibilities of 153 P. aeruginosa isolates from the United Kingdom (UK) (n = 58), Belgium (n = 44), and Germany (n = 51) collected from 118 patients during routine visits over the period from 2006 to 2012. MICs were measured by broth microdilution. Genes encoding extended-spectrum β-lactamases (ESBL), metallo-β-lactamases, and carbapenemases were detected by PCR. Pulsed-field gel electrophoresis and multilocus sequence typing were performed on isolates resistant to ≥3 antibiotic classes among the penicillins/cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, and polymyxins. Based on EUCAST/CLSI breakpoints, susceptibility rates were ≤30%/≤40% (penicillins, ceftazidime, amikacin, and ciprofloxacin), 44 to 48%/48 to 63% (carbapenems), 72%/72% (tobramycin), and 92%/78% (colistin) independent of patient age. Sixty percent of strains were multidrug resistant (MDR; European Centre for Disease Prevention and Control criteria). Genes encoding the most prevalent ESBL (BEL, PER, GES, VEB, CTX-M, TEM, SHV, and OXA), metallo-β-lactamases (VIM, IMP, and NDM), or carbapenemases (OXA-48 and KPC) were not detected. The Liverpool epidemic strain (LES) was prevalent in UK isolates only (75% of MDR isolates). Four MDR sequence type 958 (ST958) isolates were found to be spread over the three countries. The other MDR clones were evidenced in ≤3 isolates and localized in a single country. A new sequence type (ST2254) was discovered in one MDR isolate in Germany. Clonal and nonclonal isolates with different susceptibility profiles were found in 20 patients. Thus, resistance and MDR are highly prevalent in routine isolates from 3 countries, with meropenem, tobramycin, and colistin remaining the most active drugs.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27572406      PMCID: PMC5075080          DOI: 10.1128/AAC.01046-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing.

Authors:  J E Foweraker; C R Laughton; D F J Brown; D Bilton
Journal:  J Antimicrob Chemother       Date:  2005-05-09       Impact factor: 5.790

2.  Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum beta-lactamase VEB-1 in Pseudomonas aeruginosa.

Authors:  T Naas; L Poirel; A Karim; P Nordmann
Journal:  FEMS Microbiol Lett       Date:  1999-07-15       Impact factor: 2.742

3.  Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin.

Authors:  P D Lister; V M Gardner; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 4.  Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.

Authors:  N Mesaros; P Nordmann; P Plésiat; M Roussel-Delvallez; J Van Eldere; Y Glupczynski; Y Van Laethem; F Jacobs; P Lebecque; A Malfroot; P M Tulkens; F Van Bambeke
Journal:  Clin Microbiol Infect       Date:  2007-01-31       Impact factor: 8.067

5.  Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa.

Authors:  Barry Curran; Daniel Jonas; Hajo Grundmann; Tyrone Pitt; Christopher G Dowson
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

6.  Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa.

Authors:  A Deplano; O Denis; L Poirel; D Hocquet; C Nonhoff; B Byl; P Nordmann; J L Vincent; M J Struelens
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

7.  Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism.

Authors:  Sheng-Ang Ho; Tim W R Lee; Miles Denton; Steven P Conway; Keith G Brownlee
Journal:  J Cyst Fibros       Date:  2008-10-01       Impact factor: 5.482

8.  Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.

Authors:  T L Pitt; M Sparrow; M Warner; M Stefanidou
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

9.  Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis.

Authors:  Giuseppe Valenza; Dennis Tappe; Doris Turnwald; Matthias Frosch; Corinne König; Helge Hebestreit; Marianne Abele-Horn
Journal:  J Cyst Fibros       Date:  2007-08-13       Impact factor: 5.482

10.  Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  S Islam; H Oh; S Jalal; F Karpati; O Ciofu; N Høiby; B Wretlind
Journal:  Clin Microbiol Infect       Date:  2008-12-22       Impact factor: 8.067

View more
  13 in total

1.  Carbapenem-Resistant Pseudomonas aeruginosa in Chronic Lung Infection: Current Resistance Profile and Hypermutability in Patients with Cystic Fibrosis.

Authors:  Mila M Almeida; Meyvianne T Freitas; Tania W Folescu; Monica C Firmida; Ana Paula D'A Carvalho-Assef; Elizabeth A Marques; Robson S Leão
Journal:  Curr Microbiol       Date:  2021-01-06       Impact factor: 2.188

2.  The Polyaminoisoprenyl Potentiator NV716 Revives Old Disused Antibiotics against Intracellular Forms of Infection by Pseudomonas aeruginosa.

Authors:  Gang Wang; Jean-Michel Brunel; Jean-Michel Bolla; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Identification and characterization of bacteria isolated from patients with cystic fibrosis in Jordan.

Authors:  Nid'a Alshraiedeh; Farah Atawneh; Rasha Bani-Salameh; Rawan Alsharedeh; Yara Al Tall; Mohammad Alsaggar
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

4.  Quantitative proteomic reveals gallium maltolate induces an iron-limited stress response and reduced quorum-sensing in Pseudomonas aeruginosa.

Authors:  Magdalena Piatek; Darren M Griffith; Kevin Kavanagh
Journal:  J Biol Inorg Chem       Date:  2020-10-30       Impact factor: 3.358

5.  Activity of Antibiotics against Pseudomonas aeruginosa in an In Vitro Model of Biofilms in the Context of Cystic Fibrosis: Influence of the Culture Medium.

Authors:  Yvan Diaz Iglesias; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

6.  Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.

Authors:  Lois W Martin; Cynthia L Robson; Annabelle M Watts; Andrew R Gray; Claire E Wainwright; Scott C Bell; Kay A Ramsay; Timothy J Kidd; David W Reid; Ben Brockway; Iain L Lamont
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

7.  Redox Protein OsaR (PA0056) Regulates dsbM and the Oxidative Stress Response in Pseudomonas aeruginosa.

Authors:  Yujie Liu; Yibing Ma; Zhongqiang Ma; Xiao Han; Hang Qi; Jens Bo Andersen; Haijin Xu; Tim Tolker-Nielsen; Mingqiang Qiao
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

8.  Mechanisms of intrinsic resistance and acquired susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients to temocillin, a revived antibiotic.

Authors:  Hussein Chalhoub; Daniel Pletzer; Helge Weingart; Yvonne Braun; Michael M Tunney; J Stuart Elborn; Hector Rodriguez-Villalobos; Patrick Plésiat; Barbara C Kahl; Olivier Denis; Mathias Winterhalter; Paul M Tulkens; Françoise Van Bambeke
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

9.  Blocking RpoN reduces virulence of Pseudomonas aeruginosa isolated from cystic fibrosis patients and increases antibiotic sensitivity in a laboratory strain.

Authors:  M G Lloyd; J L Vossler; C T Nomura; J F Moffat
Journal:  Sci Rep       Date:  2019-04-30       Impact factor: 4.379

Review 10.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.